SDS Biotech K.K. announced consolidated earnings results for the first quarter ended June 30, 2017. For the quarter, the company reported net sales of JPY 2,915 million as compared to JPY 2,165 million for the same period last year. Operating loss was JPY 133 million as compared to JPY 448 million for the same period last year. Ordinary loss was JPY 125 million as compared to JPY 608 million for the same period last year. Net loss attributable to owners of parent was JPY 184 million as compared to JPY 335 million for the same period last year. Net income per share was JPY 23.56 as compared to JPY 42.84 for the same period last year. Net loss before taxes for the quarter was JPY 126 million as compared to JPY 607 million for the same period last year.

For the full year ending March 31, 2018, on consolidated basis, the company expects net sales of JPY 15,860 million, operating income of JPY 1,440 million, ordinary income of JPY 1,320 million, net income attributable to owners of parent of JPY 630 million and net income per share of JPY 80.45.

For the second quarter of fiscal 2018, the company expects to pay dividend of JPY 12.50 per share compared to JPY 12.50 per share paid in last year.

For the year ending March 31, 2017, the company expects to pay dividend of JPY 12.50 per share compared to JPY 12.50 per share paid in last year.